Given the important role of IFNγ/STAT1/PD-L1 axis in oncogenesis and cancer treatment, targeting the IFNγ signaling pathway as therapy is a rational and novel management in colorectal cancer (Du et al, 2022). This evidence concerns the gene STAT1 and colorectal cancer.